Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3354173 | 0.85 | TLR7 (0.59) | TLR7TLR8 | |
| SCHEMBL4157089 | 0.85 | TLR7 (0.49) | TLR7TLR8KDM4EL3MBTL1TDP1 | |
| SCHEMBL4151937 | 0.83 | TLR7 (0.48) | TLR7TLR8KDM4EL3MBTL1STING1 | |
| SCHEMBL3352700 | 0.81 | TLR7 (0.59) | TLR7TLR8 | |
| SCHEMBL1490826 | 0.80 | TLR7 (0.50) | TLR7TLR8KDM4EL3MBTL1TDP1 | |
| SCHEMBL4316046 | 0.78 | TLR7 (0.49) | TLR7TLR8STING1CYP3A4CYP2D6 | |
| SCHEMBL5129487 | 0.78 | TLR7 (0.46) | TLR7TLR8KDM4EL3MBTL1TDP1 | |
| SCHEMBL4301043 | 0.78 | TLR7 (0.47) | TLR7TLR8KDM4EL3MBTL1TDP1 | |
| SCHEMBL3357579 | 0.77 | STING1 (0.43) | TLR7TLR8KDM4EL3MBTL1TDP1 | |
| SCHEMBL1490322 | 0.77 | TLR7 (0.47) | TLR7TLR8KDM4EL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329721-B2 | Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| US-20090298821-A1 | HYDROXY AND ALKOXY SUBSTITUTED IH-IMIDAZONAPHTHYRIDINES AND METHODS | PFIZER INC. | 2009-12-03 | — | — | US | disclosed |
| WO-2007106854-A2 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZONAPHTHYRIDINES AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298821-A1 | HYDROXY AND ALKOXY SUBSTITUTED IH-IMIDAZONAPHTHYRIDINES AND METHODS | IL2, IL4, IFNG | TLR7 61/4885TLR8 104/4885KDM4E 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.